Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07842679

Cognitive Impairment in Older Adults With Hematologic Malignancies

This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Cognitive Impairment Chemotherapy Effect Cognition Disorders Cognitive Dysfunction Hematologic Diseases Hematologic Malignancies Hematologic Neoplasms Hemic and Lymphatic Diseases Mental Disorders Neoplasms Neoplasms by Site Neurocognitive Disorders

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Cognitive impairment is common among older adults with cancer and may affect treatment adherence and independence. This observational study will include adults aged 65 years or older with confirmed hematologic malignancies who are currently receiving chemotherapy.

Participants will undergo cognitive assessment using the Montreal Cognitive Assessment (MoCA) and functional assessment using the Katz Index of Activities of Daily Living (ADL) and Lawton Instrumental Activities of Daily Living (IADL).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Age 65 years or older
  • Confirmed diagnosis of hematologic malignancy
  • Currently receiving chemotherapy
  • Able to communicate and participate in cognitive assessment
  • Written informed consent

Exclusion criteria

  • - Previously diagnosed dementia before the diagnosis of malignancy
  • Delirium at the time of assessment
  • Severe visual or hearing impairment interfering with cognitive testing
  • History of major neurological disorders affecting cognition
  • Severe psychiatric illness affecting cognitive assessment
  • Critically ill patients unable to complete study assessment

Treatment and study plan

Primary outcomes

  1. Prevalence of cognitive impairment

    Time frame: Baseline

    Proportion of participants with cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score less than 26.

Secondary outcomes

  1. Mean MoCA score

    Time frame: Baseline

    Mean Montreal Cognitive Assessment score (range 0-30).

  2. Mean Katz ADL score

    Time frame: Baseline

    Mean Katz Index of Activities of Daily Living score

  3. Mean Lawton IADL score

    Time frame: Baseline

    Mean Lawton Instrumental Activities of Daily Living score.

  4. Proportion with impaired activities of daily living

    Time frame: Baseline

    Proportion of participants with impaired Katz ADL score.

  5. Proportion with impaired instrumental activities of daily living

    Time frame: Baseline

    Proportion of participants with impaired Lawton IADL score.

Interested in participating?

Not yet recruiting

Trial opening soon.

Get Notified

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Prevalence of Cognitive Impairment and Its Association With Activities of Daily Living Among Older Adults With Hematologic Malignancies Receiving Chemotherapy

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Sep 25, 2026
Registry last updated
Sep 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.